Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2013

Open Access 01-12-2013 | Original investigation

Impact of post-challenge hyperglycemia on clinical outcomes in japanese patients with stable angina undergoing percutaneous coronary intervention

Authors: Shoichi Kuramitsu, Hiroyoshi Yokoi, Takenori Domei, Akihiro Nomura, Hirotoshi Watanabe, Kyohei Yamaji, Yoshimitsu Soga, Takeshi Arita, Katsuhiro Kondo, Shinichi Shirai, Kenji Ando, Koyu Sakai, Masashi Iwabuchi, Hedeyuki Nosaka, Masakiyo Nobuyoshi

Published in: Cardiovascular Diabetology | Issue 1/2013

Login to get access

Abstract

Background

Post-challenge hyperglycemia (PH) is well-established as one of risk factors for coronary artery disease. However, it remains unclear whether PH affects clinical outcomes in patients with stable angina undergoing percutaneous coronary intervention (PCI).

Methods

A total of 828 patients with stable angina undergoing PCI were retrospectively analyzed. Of these, 452 patients with previously diagnosed diabetes mellitus (DM) or fasting plasma glucose (PG) ≥126 mg/dl and HbA1c ≥6.5% were defined as known DM. The remaining 376 patients were divided into the two groups according to 2-h PG: PH (2-h PG ≥140 mg/dl, n=236) and normal glucose tolerance (NGT, 2-h PG <140 mg/dl, n=140). We assessed the rate of major adverse cardiovascular events (MACE), defined as a composite of cardiovascular death, myocardial infarction, stroke, and clinically-driven revascularization.

Results

During the median follow-up of 4.3 years, the MACE rate was significantly higher in the DM and PH groups than the NGT group (39.3% vs. 20.7%, P <0.001; 31.4% vs. 20.7%, P=0.044, respectively). Compared with the NGT group, the cumulative incidence of revascularization was significantly higher in the DM group (35.1% vs. 18.5%, P <0.001) and tended to be higher in the PH group (27.1% vs. 18.5%, P=0.067). In the multivariate analysis, known DM (Hazard ratio [HR]: 2.16, 95% confidence interval (CI): 1.49-3.27, P < 0.001), PH (HR: 1.62, 95% CI: 1.07-2.53, P = 0.023), LDL-C >100 mg/dl (HR: 1.62, 95% CI: 1.26 to 2.10, P < 0.001), and previous stroke (HR: 1.47, 95% CI: 1.03-2.04, P = 0.034) were predictors of MACE.

Conclusion

PH is associated with future cardiovascular events in patients with stable angina undergoing PCI.
Appendix
Available only for authorised users
Literature
1.
go back to reference National Institute of Diabetes and Digestive and Kidney Diseases: National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2005. 2005, Bethesda, MD: US Department of Health and Human Services, National Institute of Health National Institute of Diabetes and Digestive and Kidney Diseases: National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2005. 2005, Bethesda, MD: US Department of Health and Human Services, National Institute of Health
2.
go back to reference The DECODE study group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2 h diagnostic criteria. Arch Intern Med. 2001, 161: 397-405. 10.1001/archinte.161.3.397.CrossRef The DECODE study group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2 h diagnostic criteria. Arch Intern Med. 2001, 161: 397-405. 10.1001/archinte.161.3.397.CrossRef
3.
go back to reference Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M: Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke. 2003, 34: 2349-2354. 10.1161/01.STR.0000090348.52943.A2.CrossRefPubMed Kubo M, Kiyohara Y, Kato I, Tanizaki Y, Arima H, Tanaka K, Nakamura H, Okubo K, Iida M: Trends in the incidence, mortality, and survival rate of cardiovascular disease in a Japanese community: the Hisayama study. Stroke. 2003, 34: 2349-2354. 10.1161/01.STR.0000090348.52943.A2.CrossRefPubMed
4.
go back to reference Saito I: Epidemiological evidence of type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease in Japan. Circ J. 2012, 76: 1066-1073. 10.1253/circj.CJ-11-1519.CrossRefPubMed Saito I: Epidemiological evidence of type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease in Japan. Circ J. 2012, 76: 1066-1073. 10.1253/circj.CJ-11-1519.CrossRefPubMed
5.
go back to reference Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO: Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. Am Heart J. 1986, 112: 825-836. 10.1016/0002-8703(86)90481-3.CrossRefPubMed Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO: Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial. Am Heart J. 1986, 112: 825-836. 10.1016/0002-8703(86)90481-3.CrossRefPubMed
6.
go back to reference Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM, Wong TY, McNeil J, Shaw JE: Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study. Circulation. 2007, 116: 151-157. 10.1161/CIRCULATIONAHA.106.685628.CrossRefPubMed Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM, Wong TY, McNeil J, Shaw JE: Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study. Circulation. 2007, 116: 151-157. 10.1161/CIRCULATIONAHA.106.685628.CrossRefPubMed
7.
go back to reference Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP: Insulin resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000, 101: 975-980. 10.1161/01.CIR.101.9.975.CrossRefPubMed Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP: Insulin resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000, 101: 975-980. 10.1161/01.CIR.101.9.975.CrossRefPubMed
8.
go back to reference Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: The Funagata Diabetes Study. Diabetes Care. 1999, 22: 920-924. 10.2337/diacare.22.6.920.CrossRefPubMed Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: The Funagata Diabetes Study. Diabetes Care. 1999, 22: 920-924. 10.2337/diacare.22.6.920.CrossRefPubMed
9.
go back to reference Qiao Q, Nakagami T, Tuomilehto J, Borch-Johnsen K, Balkau B, Iwamoto Y, Tajima N, International Diabetes Epidemiology Group; DECODA Study Group: Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia. 2000, 43: 1470-1475. 10.1007/s001250051557.CrossRefPubMed Qiao Q, Nakagami T, Tuomilehto J, Borch-Johnsen K, Balkau B, Iwamoto Y, Tajima N, International Diabetes Epidemiology Group; DECODA Study Group: Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia. 2000, 43: 1470-1475. 10.1007/s001250051557.CrossRefPubMed
10.
go back to reference Levitan EB, Song Y, Ford ES, Liu S: Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 2004, 164: 2147-2155. 10.1001/archinte.164.19.2147.CrossRefPubMed Levitan EB, Song Y, Ford ES, Liu S: Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 2004, 164: 2147-2155. 10.1001/archinte.164.19.2147.CrossRefPubMed
11.
go back to reference Niskanen L, Turpeinen A, Penttila I, Uusitupa MI: Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care. 1998, 21: 1861-1869. 10.2337/diacare.21.11.1861.CrossRefPubMed Niskanen L, Turpeinen A, Penttila I, Uusitupa MI: Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis. Diabetes Care. 1998, 21: 1861-1869. 10.2337/diacare.21.11.1861.CrossRefPubMed
12.
go back to reference Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002, 359: 2140-2144. 10.1016/S0140-6736(02)09089-X.CrossRefPubMed Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002, 359: 2140-2144. 10.1016/S0140-6736(02)09089-X.CrossRefPubMed
13.
go back to reference Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyo¨ra¨la¨ K, Simoons M, Standl E, Soler-Soler J, Ohrvik J: The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J. 2004, 25: 1880-1890. 10.1016/j.ehj.2004.07.027.CrossRefPubMed Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyo¨ra¨la¨ K, Simoons M, Standl E, Soler-Soler J, Ohrvik J: The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J. 2004, 25: 1880-1890. 10.1016/j.ehj.2004.07.027.CrossRefPubMed
14.
go back to reference Hu DY, Pan CY, Yu JM: for the China Heart Survey Group. The relationship between coronary artery disease an abnormal glucose regulation in China: the China Heart Survey. Eur Heart J. 2006, 27: 2573-2579. 10.1093/eurheartj/ehl207.CrossRefPubMed Hu DY, Pan CY, Yu JM: for the China Heart Survey Group. The relationship between coronary artery disease an abnormal glucose regulation in China: the China Heart Survey. Eur Heart J. 2006, 27: 2573-2579. 10.1093/eurheartj/ehl207.CrossRefPubMed
15.
go back to reference ADA: Classification of Diabetes mellitus. Diabetes Care. 2008, 31: S55-S60.CrossRef ADA: Classification of Diabetes mellitus. Diabetes Care. 2008, 31: S55-S60.CrossRef
16.
go back to reference Sourij H, Saely CH, Schmid F, Zweiker R, Marte T, Wascher TC, Drexel H: Post-challenge hyperglycaemia is strongly associated with future macrovascular events and total mortality in angiographied coronary patients. Eur Heart J. 2010, 31: 1583-1590. 10.1093/eurheartj/ehq099.CrossRefPubMed Sourij H, Saely CH, Schmid F, Zweiker R, Marte T, Wascher TC, Drexel H: Post-challenge hyperglycaemia is strongly associated with future macrovascular events and total mortality in angiographied coronary patients. Eur Heart J. 2010, 31: 1583-1590. 10.1093/eurheartj/ehq099.CrossRefPubMed
17.
go back to reference Japan Diabetes Clinical Data Management Study Group: The status of diabetes control and antidiabetic drug therapy in Japan – A cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM1). Diab Res Clin Pract. 2006, 73: 198-204. 10.1016/j.diabres.2006.01.013.CrossRef Japan Diabetes Clinical Data Management Study Group: The status of diabetes control and antidiabetic drug therapy in Japan – A cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM1). Diab Res Clin Pract. 2006, 73: 198-204. 10.1016/j.diabres.2006.01.013.CrossRef
18.
go back to reference Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myocardial infarction. Circulation. 2007, 116: 2634-2653. 10.1161/CIRCULATIONAHA.107.187397.CrossRefPubMed Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction: Universal definition of myocardial infarction. Circulation. 2007, 116: 2634-2653. 10.1161/CIRCULATIONAHA.107.187397.CrossRefPubMed
19.
go back to reference Tamita K, Katayama M, Takagi T, Akasaka T, Yamamuro A, Kaji S, Morioka S, Kihara Y: Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in patients with acute myocardial infarction. Circ J. 2007, 71: 834-841. 10.1253/circj.71.834.CrossRefPubMed Tamita K, Katayama M, Takagi T, Akasaka T, Yamamuro A, Kaji S, Morioka S, Kihara Y: Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in patients with acute myocardial infarction. Circ J. 2007, 71: 834-841. 10.1253/circj.71.834.CrossRefPubMed
20.
go back to reference de la Hera JM, Delgado E, Hernández E, García-Ruiz JM, Vegas JM, Avanzas P, Lozano I, Barriales-Villa R, Hevia S, Martín JS, Alvarez F, Morís C: Prevalence and outcome of newly detected diabetes in patients who undergo percutaneous coronary intervention. Eur Hear J. 2009, 31: 2614-2621.CrossRef de la Hera JM, Delgado E, Hernández E, García-Ruiz JM, Vegas JM, Avanzas P, Lozano I, Barriales-Villa R, Hevia S, Martín JS, Alvarez F, Morís C: Prevalence and outcome of newly detected diabetes in patients who undergo percutaneous coronary intervention. Eur Hear J. 2009, 31: 2614-2621.CrossRef
21.
go back to reference Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Rydén L: Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J. 2004, 25: 1990-1997. 10.1016/j.ehj.2004.09.021.CrossRefPubMed Bartnik M, Malmberg K, Norhammar A, Tenerz A, Ohrvik J, Rydén L: Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction. Eur Heart J. 2004, 25: 1990-1997. 10.1016/j.ehj.2004.09.021.CrossRefPubMed
22.
go back to reference Ning F, Zhang L, Dekker JM, Onat A, Stehouwer CD, Yudkin JS, Laatikainen T, Tuomilehto J, Pyörälä K, Qiao Q, DECODE Finnish and Swedish Study Investigators: Development of coronary heart disease and ischemic stroke in relation to fasting and 2-hour plasma glucose levels in the normal range. Cardiovasc Diabetol. 2012, 11: 76-10.1186/1475-2840-11-76.PubMedCentralCrossRefPubMed Ning F, Zhang L, Dekker JM, Onat A, Stehouwer CD, Yudkin JS, Laatikainen T, Tuomilehto J, Pyörälä K, Qiao Q, DECODE Finnish and Swedish Study Investigators: Development of coronary heart disease and ischemic stroke in relation to fasting and 2-hour plasma glucose levels in the normal range. Cardiovasc Diabetol. 2012, 11: 76-10.1186/1475-2840-11-76.PubMedCentralCrossRefPubMed
23.
go back to reference Schinner S, Füth R, Kempf K, Martin S, Willenberg HS, Schott M, Dinh W, Scherbaum WA, Lankisch M: A progressive increase in cardiovascular risk assessed by coronary angiography in non-diabetic patients at sub-diabetic glucose levels. Cardiovasc Diabetol. 2011, 10: 56-10.1186/1475-2840-10-56.PubMedCentralCrossRefPubMed Schinner S, Füth R, Kempf K, Martin S, Willenberg HS, Schott M, Dinh W, Scherbaum WA, Lankisch M: A progressive increase in cardiovascular risk assessed by coronary angiography in non-diabetic patients at sub-diabetic glucose levels. Cardiovasc Diabetol. 2011, 10: 56-10.1186/1475-2840-10-56.PubMedCentralCrossRefPubMed
24.
go back to reference Henareh L, Agewall S: 2-h postchallenge plasma glucose predicts cardiovascular events in patients with myocardial infarction without known diabetes mellitus. Cardiovasc Diabetol. 2012, 11: 93-10.1186/1475-2840-11-93.PubMedCentralCrossRefPubMed Henareh L, Agewall S: 2-h postchallenge plasma glucose predicts cardiovascular events in patients with myocardial infarction without known diabetes mellitus. Cardiovasc Diabetol. 2012, 11: 93-10.1186/1475-2840-11-93.PubMedCentralCrossRefPubMed
25.
go back to reference Mazurek M, Kowalczyk J, Lenarczyk R, Zielinska T, Sedkowska A, Pruszkowska-Skrzep P, Swiatkowski A, Sredniawa B, Kowalski O, Polonski L, Strojek K, Kalarus Z: The prognostic value of different glucose abnormalities in patients with acute myocardial infarction treated invasively. Cardiovasc Diabetol. 2012, 11: 78-10.1186/1475-2840-11-78.PubMedCentralCrossRefPubMed Mazurek M, Kowalczyk J, Lenarczyk R, Zielinska T, Sedkowska A, Pruszkowska-Skrzep P, Swiatkowski A, Sredniawa B, Kowalski O, Polonski L, Strojek K, Kalarus Z: The prognostic value of different glucose abnormalities in patients with acute myocardial infarction treated invasively. Cardiovasc Diabetol. 2012, 11: 78-10.1186/1475-2840-11-78.PubMedCentralCrossRefPubMed
26.
go back to reference Haller H: Postprandial glucose and vascular disease. Diabet Med. 1997, 14: S50-S56. 10.1002/(SICI)1096-9136(199708)14:3+<S50::AID-DIA445>3.3.CO;2-T.CrossRefPubMed Haller H: Postprandial glucose and vascular disease. Diabet Med. 1997, 14: S50-S56. 10.1002/(SICI)1096-9136(199708)14:3+<S50::AID-DIA445>3.3.CO;2-T.CrossRefPubMed
27.
go back to reference Moreno PR, Fuster V: New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol. 2004, 44: 2293-2300. 10.1016/j.jacc.2004.07.060.CrossRefPubMed Moreno PR, Fuster V: New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol. 2004, 44: 2293-2300. 10.1016/j.jacc.2004.07.060.CrossRefPubMed
28.
go back to reference Bansilal S, Farkouh ME, Fuster V: Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol. 2007, 99: 6B-14B.CrossRefPubMed Bansilal S, Farkouh ME, Fuster V: Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol. 2007, 99: 6B-14B.CrossRefPubMed
29.
go back to reference Nishimoto Y, Miyazaki Y, Toki Y, Murakami R, Shinoda M, Fukushima A, Kanayama H: Enhanced secretion of insulin plays a role in the development of atherosclerosis and restenosis of coronary arteries: elective percutaneous transluminal coronary angioplasty in patients with effort angina. J Am Coll Cardiol. 1998, 32: 1624-1629. 10.1016/S0735-1097(98)00428-8.CrossRefPubMed Nishimoto Y, Miyazaki Y, Toki Y, Murakami R, Shinoda M, Fukushima A, Kanayama H: Enhanced secretion of insulin plays a role in the development of atherosclerosis and restenosis of coronary arteries: elective percutaneous transluminal coronary angioplasty in patients with effort angina. J Am Coll Cardiol. 1998, 32: 1624-1629. 10.1016/S0735-1097(98)00428-8.CrossRefPubMed
30.
go back to reference Osanai H, Kanayama H, Miyazaki Y, Fukushima A, Shinoda M, Ito T: Usefulness of enhanced insulin secretion during an oral glucose tolerance test as a predictor of restenosis after direct percutaneous transluminal coronary angioplasty during acute myocardial infarction in patients without diabetes mellitus. Am J Cardiol. 1998, 81: 698-701. 10.1016/S0002-9149(97)01021-7.CrossRefPubMed Osanai H, Kanayama H, Miyazaki Y, Fukushima A, Shinoda M, Ito T: Usefulness of enhanced insulin secretion during an oral glucose tolerance test as a predictor of restenosis after direct percutaneous transluminal coronary angioplasty during acute myocardial infarction in patients without diabetes mellitus. Am J Cardiol. 1998, 81: 698-701. 10.1016/S0002-9149(97)01021-7.CrossRefPubMed
31.
go back to reference Nakamura N, Ueno Y, Tsuchiyama Y, Koike Y, Gohda M, Satani O: Isolated post-challenge hyperglycemia in patients with normal fasting glucose concentration exaggerates neointimal hyperplasia after coronary stent implantation. Circ J. 2003, 67: 61-67. 10.1253/circj.67.61.CrossRefPubMed Nakamura N, Ueno Y, Tsuchiyama Y, Koike Y, Gohda M, Satani O: Isolated post-challenge hyperglycemia in patients with normal fasting glucose concentration exaggerates neointimal hyperplasia after coronary stent implantation. Circ J. 2003, 67: 61-67. 10.1253/circj.67.61.CrossRefPubMed
32.
go back to reference Lima-Filho MO, Figueiredo GL, Foss-Freitas MC, Foss MC, Marin-Neto JA: Predictors of restenosis after percutaneous coronary intervention using bare-metal stents: a comparison between patients with and without dysglycemia. Braz J Med Biol Res. 2010, 43: 572-579. 10.1590/S0100-879X2010007500051.CrossRefPubMed Lima-Filho MO, Figueiredo GL, Foss-Freitas MC, Foss MC, Marin-Neto JA: Predictors of restenosis after percutaneous coronary intervention using bare-metal stents: a comparison between patients with and without dysglycemia. Braz J Med Biol Res. 2010, 43: 572-579. 10.1590/S0100-879X2010007500051.CrossRefPubMed
33.
go back to reference Kataoka Y, Yasuda S, Miyamoto Y, Sase K, Kosuge M, Kimura K, Yoshimasa Y, Miyazaki S, DIANA study investigators: Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients. Circ J. 2012, 76: 712-720. 10.1253/circj.CJ-11-1011.CrossRefPubMed Kataoka Y, Yasuda S, Miyamoto Y, Sase K, Kosuge M, Kimura K, Yoshimasa Y, Miyazaki S, DIANA study investigators: Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients. Circ J. 2012, 76: 712-720. 10.1253/circj.CJ-11-1011.CrossRefPubMed
34.
go back to reference Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008, 359: 1577-1589. 10.1056/NEJMoa0806470.CrossRefPubMed Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008, 359: 1577-1589. 10.1056/NEJMoa0806470.CrossRefPubMed
35.
go back to reference Lankisch M, Füth R, Schotes D, Rose B, Lapp H, Rathmann W, Haastert B, Gülker H, Scherbaum WA, Martin S: High prevalence of undiagnosed impaired glucose regulation and diabetes mellitus in patients scheduled for an elective coronary angiography. Clin Res Cardiol. 2006, 95: 80-87. 10.1007/s00392-006-0328-4.CrossRefPubMed Lankisch M, Füth R, Schotes D, Rose B, Lapp H, Rathmann W, Haastert B, Gülker H, Scherbaum WA, Martin S: High prevalence of undiagnosed impaired glucose regulation and diabetes mellitus in patients scheduled for an elective coronary angiography. Clin Res Cardiol. 2006, 95: 80-87. 10.1007/s00392-006-0328-4.CrossRefPubMed
36.
go back to reference de la Hera JM, García-Ruiz JM, Martínez-Camblor P, Martín M, Tellería AL, Corros C, Torres F, Fernández-Cimadevilla OC, Alvarez-Pichel I, Capín E, Avanzas P, Delgado E: Real incidence of diabetes mellitus in a coronary disease population. Am J Cardiol. 2013, 11: 333-338.CrossRef de la Hera JM, García-Ruiz JM, Martínez-Camblor P, Martín M, Tellería AL, Corros C, Torres F, Fernández-Cimadevilla OC, Alvarez-Pichel I, Capín E, Avanzas P, Delgado E: Real incidence of diabetes mellitus in a coronary disease population. Am J Cardiol. 2013, 11: 333-338.CrossRef
37.
go back to reference de la Hera JM, Delgado E, Martínez-Camblor P, Vegas JM, García-Ruiz JM, Rodriguez-Lambert JL: Oral glucose tolerance test as a tool for patient improvement after percutaneous coronary intervention. Rev Esp Cardiol (Engl Ed). 2012, 65: 1054-1056. 10.1016/j.recesp.2012.02.023.CrossRef de la Hera JM, Delgado E, Martínez-Camblor P, Vegas JM, García-Ruiz JM, Rodriguez-Lambert JL: Oral glucose tolerance test as a tool for patient improvement after percutaneous coronary intervention. Rev Esp Cardiol (Engl Ed). 2012, 65: 1054-1056. 10.1016/j.recesp.2012.02.023.CrossRef
38.
go back to reference American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012, 1: S64-S71.CrossRef American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012, 1: S64-S71.CrossRef
39.
go back to reference Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007, 28: 88-136.CrossRefPubMed Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Ostergren J, Tuomilehto J, Thrainsdottir I, Vanhorebeek I, Stramba-Badiale M, Lindgren P, Qiao Q, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007, 28: 88-136.CrossRefPubMed
40.
go back to reference Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004, 350: 1495-1504. 10.1056/NEJMoa040583.CrossRefPubMed Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM: Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004, 350: 1495-1504. 10.1056/NEJMoa040583.CrossRefPubMed
41.
go back to reference Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN, REVERSAL Investigators: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004, 291: 1071-1080. 10.1001/jama.291.9.1071.CrossRefPubMed Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN, REVERSAL Investigators: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004, 291: 1071-1080. 10.1001/jama.291.9.1071.CrossRefPubMed
42.
go back to reference Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M, COSMOS Investigators: Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J. 2009, 73: 2110-2117. 10.1253/circj.CJ-09-0358.CrossRefPubMed Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M, COSMOS Investigators: Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J. 2009, 73: 2110-2117. 10.1253/circj.CJ-09-0358.CrossRefPubMed
43.
go back to reference Daida H, Takayama T, Hiro T, Yamagishi M, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M, COSMOS Investigators: High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Cardiovasc Diabetol. 2012, 11: 87-10.1186/1475-2840-11-87.PubMedCentralCrossRefPubMed Daida H, Takayama T, Hiro T, Yamagishi M, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M, COSMOS Investigators: High HbA1c levels correlate with reduced plaque regression during statin treatment in patients with stable coronary artery disease: results of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Cardiovasc Diabetol. 2012, 11: 87-10.1186/1475-2840-11-87.PubMedCentralCrossRefPubMed
44.
go back to reference Bayturan O, Kapadia S, Nicholls SJ, Tuzcu EM, Shao M, Uno K, Shreevatsa A, Lavoie AJ, Wolski K, Schoenhagen P, Nissen SE: Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol. 2010, 55: 2736-2742. 10.1016/j.jacc.2010.01.050.CrossRefPubMed Bayturan O, Kapadia S, Nicholls SJ, Tuzcu EM, Shao M, Uno K, Shreevatsa A, Lavoie AJ, Wolski K, Schoenhagen P, Nissen SE: Clinical predictors of plaque progression despite very low levels of low-density lipoprotein cholesterol. J Am Coll Cardiol. 2010, 55: 2736-2742. 10.1016/j.jacc.2010.01.050.CrossRefPubMed
45.
go back to reference Ye Y, Xie H, Zhao X, Zhang S: The oral glucose tolerance test for the diagnosis of diabetes mellitus in patients during acute coronary syndrome hospitalization: a meta-analysis of diagnostic test accuracy. Cardiovasc Diabetol. 2012, 11: 155-10.1186/1475-2840-11-155.PubMedCentralCrossRefPubMed Ye Y, Xie H, Zhao X, Zhang S: The oral glucose tolerance test for the diagnosis of diabetes mellitus in patients during acute coronary syndrome hospitalization: a meta-analysis of diagnostic test accuracy. Cardiovasc Diabetol. 2012, 11: 155-10.1186/1475-2840-11-155.PubMedCentralCrossRefPubMed
Metadata
Title
Impact of post-challenge hyperglycemia on clinical outcomes in japanese patients with stable angina undergoing percutaneous coronary intervention
Authors
Shoichi Kuramitsu
Hiroyoshi Yokoi
Takenori Domei
Akihiro Nomura
Hirotoshi Watanabe
Kyohei Yamaji
Yoshimitsu Soga
Takeshi Arita
Katsuhiro Kondo
Shinichi Shirai
Kenji Ando
Koyu Sakai
Masashi Iwabuchi
Hedeyuki Nosaka
Masakiyo Nobuyoshi
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2013
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-12-74

Other articles of this Issue 1/2013

Cardiovascular Diabetology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine